Jonathan Pachter
JP
Jonathan Pachter
Chief Scientific Officer
Rate
About
Dr. Jonathan Pachter is the Chief Scientific Officer at Verastem Oncology, with over 30 years of experience in leading discovery and translational research for small molecule and monoclonal antibody anti-cancer therapeutics. He has made significant contributions to the development of several cancer treatments, including advancing five small molecules into development at OSI Pharmaceuticals and progressing three agents at Schering-Plough. Dr. Pachter holds a Ph.D. from Baylor College of Medicine and completed his postdoctoral work in pharmacology at Yale University School of Medicine.
Frequently asked
Who is Jonathan Pachter?
Dr. Jonathan Pachter is the Chief Scientific Officer at Verastem Oncology, with over 30 years of experience in leading discovery and translational research for small molecule and monoclonal antibody anti-cancer therapeutics. He has made significant contributions to the development of several cancer treatments, including advancing five small molecules into development at OSI Pharmaceuticals and pro…
What is Jonathan Pachter's current role?
Jonathan Pachter is currently Chief Scientific Officer.
Comments
No comments yet. Be the first to share your take.
Profile
About Jonathan Pachter
Jonathan Pachter is Chief Scientific Officer. This profile tracks their companies, funding activity, and news mentions across the AI ecosystem.